Immunotherapy

Dual targeting of TGF-β and PD-L1 via a bifunctional anti-PD-L1/TGF-βRII agent: status of preclinical and clinical advances
Hanne Lind, Sofia R Gameiro, Caroline Jochems, Renee N. Donahue, Julius Strauss, James L Gulley, Claudia Palena, Jeffrey Schlom

Journal for ImmunoTherapy of Cancer Feb 2020, 8 (1) e000433; DOI: 10.1136/jitc-2019-000433
Comparison of commonly used solid tumor targeted gene sequencing panels for estimating tumor mutation burden shows analytical and prognostic concordance within the cancer genome atlas cohort
Nicholas Bevins, Shulei Sun, Zied Gaieb, John A Thorson, Sarah S Murray

Journal for ImmunoTherapy of Cancer Mar 2020, 8 (1) e000613; DOI: 10.1136/jitc-2020-000613
Diffuse pneumonitis from coronavirus HKU1 on checkpoint inhibitor therapy
Michael T Serzan, Princy N Kumar, Michael B Atkins

Journal for ImmunoTherapy of Cancer May 2020, 8 (1) e000898; DOI: 10.1136/jitc-2020-000898
IL-15 superagonist RLI has potent immunostimulatory properties on NK cells: implications for antimetastatic treatment
Mélanie Desbois, Coralie Béal, Mélinda Charrier, Benjamin Besse, Guillaume Meurice, Nicolas Cagnard, Yannick Jacques, David Béchard, Lydie Cassard, Nathalie Chaput

Journal for ImmunoTherapy of Cancer Jun 2020, 8 (1) e000632; DOI: 10.1136/jitc-2020-000632
Hyperprogression to camrelizumab in a patient with esophageal squamous cell carcinoma harboring EGFR kinase domain duplication
Wei Wang, Meihong Wu, Minglu Liu, Zhengqing Yan, Guoqiang Wang, Dongliang Mao, Mei Wang

Journal for ImmunoTherapy of Cancer Jun 2020, 8 (1) e000793; DOI: 10.1136/jitc-2020-000793
On the mechanism of anti-CD39 immune checkpoint therapy
David Allard, Bertrand Allard, John Stagg

Journal for ImmunoTherapy of Cancer Feb 2020, 8 (1) e000186; DOI: 10.1136/jitc-2019-000186
LAG3 (LAG-3, CD223) DNA methylation correlates with LAG3 expression by tumor and immune cells, immune cell infiltration, and overall survival in clear cell renal cell carcinoma
Niklas Klümper, Damian J Ralser, Emma Grace Bawden, Jenny Landsberg, Romina Zarbl, Glen Kristiansen, Marieta Toma, Manuel Ritter, Michael Hölzel, Jörg Ellinger, Dimo Dietrich

Journal for ImmunoTherapy of Cancer Mar 2020, 8 (1) e000552; DOI: 10.1136/jitc-2020-000552
Flow cytometric evaluation of CD38 expression levels in the newly diagnosed T-cell acute lymphoblastic leukemia and the effect of chemotherapy on its expression in measurable residual disease, refractory disease and relapsed disease: an implication for anti-CD38 immunotherapy
Prashant Ramesh Tembhare, Harshini Sriram, Twinkle Khanka, Gaurav Chatterjee, Devasis Panda, Sitaram Ghogale, Yajamanam Badrinath, Nilesh Deshpande, Nikhil V Patkar, Gaurav Narula, Bhausaheb Bagal, Hasmukh Jain, Manju Sengar, Navin Khattry, Shripad Banavali, Sumeet Gujral, Papagudi G Subramanian

Journal for ImmunoTherapy of Cancer May 2020, 8 (1) e000630; DOI: 10.1136/jitc-2020-000630
Stromal LAG-3⁺ cells infiltration defines poor prognosis subtype muscle-invasive bladder cancer with immunoevasive contexture
Han Zeng, Quan Zhou, Zewei Wang, Hongyu Zhang, Zhaopei Liu, Qiuren Huang, Jiajun Wang, Yuan Chang, Qi Bai, Yu Xia, Yiwei Wang, Le Xu, Bo Dai, Jianming Guo, Li Liu, Yu Zhu, Jiejie Xu

Journal for ImmunoTherapy of Cancer Jun 2020, 8 (1) e000651; DOI: 10.1136/jitc-2020-000651
Small cell transformation of non-small cell lung cancer on immune checkpoint inhibitors: uncommon or under-recognized?
Kartik Sehgal, Andreas Varkaris, Hollis Viray, Paul A VanderLaan, Deepa Rangachari, Daniel B Costa

Journal for ImmunoTherapy of Cancer Jun 2020, 8 (1) e000697; DOI: 10.1136/jitc-2020-000697

Main menu

Immunotherapy

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

Immunotherapy

Pages